A study on RGB-5088 for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have type 1 diabetes (even if you have had an organ transplant like a liver or kidney).
- Your stimulated C-peptide level is less than 0.3 ng/mL (a test that shows how much insulin your body still makes).
- You have had at least one severe low blood sugar event in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental drug (NNC0487-0111) designed to help regulate insulin levels in adults with type 2 diabetes. Researchers want to see if it works safely and effectively when combined with your current diabetes medications.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
This study tests if a very low-carb (ketogenic) diet is safe and helps control blood sugar in people with type 1 diabetes. You would follow the diet for a period and use a continuous glucose monitor to track your levels.
This study tests an experimental medicine called RGB-5088 for people with type 2 diabetes who are already using insulin. The goal is to see if it can safely improve blood sugar control when added to your current diabetes management.
This study tests a program to help people with type 1 diabetes improve their blood sugar control using continuous glucose monitors, insulin pumps, and education sessions. It includes remote monitoring and camp activities for some participants.
This study tests a new medication, MTX228, to see if it can help people with type 1 diabetes who still make some insulin. It may slow the loss of your own insulin production and improve blood sugar control.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.